You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

130 Results
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Status: Current
ID: ES SMG-3
Jan 2019
Cancer facts
Feb 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: Final
May 2018
Cancer facts
May 2019
Document
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Blog posts

Blog Category: Our Work

Dr. Leta Forbes, Medical OncologistProvincial Head, Systemic Treatment ProgramOntario Health (Cancer Care Ontario) Reactions to the injection of...
Sep 2019
Document
Sep 2019
Document
Oct 2019
Document
Jan 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
gemcitabine,
CISplatin,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2020

Pages